Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC

Summary

This study aims to explore time-of-day of administration of immunochemotherapy on the efficacy for treatment naive advanced non-small cell lung cancer.

Timeline

Start

2022-09-23

Primary completion

2024-12-02

Completion

2026-04-30

Outcome

Met primary endpoint

paper corresponding to a hazard ratio (HR) for earlier disease progression of 0.40 (95% CI = 0.29-0.55; P < 0.001). PMID 41629425 ↗

paper our study indicates that early ToD immunochemotherapy substantially improves PFS and OS PMID 41629425 ↗

Publications

• Huang Z, Zeng L, Ruan Z, Zeng Q, Yan H, Jiang W, Xiong Y, Zhou C, Yang H, Liu L, Dai J, Zou N, Xu S, Wang Y, Wang Z, Deng J, Chen X, Wang J, Xiang H, Li X, Duchemann B, Chen G, Xia Y, Mok T, Scheiermann C, Levi F, Yang N, Zhang Y. Time-of-day immunochemotherapy in non-small cell lung cancer: a randomized phase 3 trial. Nat Med. 2026 Apr;32(4):1233-1240. doi: 10.1038/s41591-025-04181-w. Epub 2026 Feb 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pembrolizumab	Monoclonal antibody	—	—
Subject	Sintilimab	Monoclonal antibody	—	—

Indications